Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Pediatr Infect Dis J ; 39(11): 1040-1042, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32773656

RESUMO

Since December 2019, severe acute respiratory syndrome coronavirus 2 infection has spread worldwide. We all are concerned about immunocompromised children, especially hematologic and oncologic pediatric patients. We want to share our experience with 2 pediatric cancer patients with severe acute respiratory syndrome coronavirus 2 infection. Both presented mild disease and good outcome. No respiratory symptoms were identified, but both developed diarrhea, one probably secondary to lopinavir/ritonavir. Pediatric cancer patients may have milder disease than adults, but larger studies are needed to make conclusions.


Assuntos
Infecções por Coronavirus/diagnóstico , Neoplasias Renais/virologia , Pneumonia Viral/diagnóstico , Sarcoma de Ewing/virologia , Tumor de Wilms/virologia , Adolescente , Betacoronavirus/isolamento & purificação , COVID-19 , Criança , Pré-Escolar , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Diarreia/etiologia , Diarreia/virologia , Feminino , Humanos , Neoplasias Renais/epidemiologia , Lopinavir/uso terapêutico , Pandemias , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/epidemiologia , Ritonavir/uso terapêutico , SARS-CoV-2 , Sarcoma de Ewing/epidemiologia , Espanha/epidemiologia , Tumor de Wilms/epidemiologia
2.
An. pediatr. (2003. Ed. impr.) ; 92(3): 141-146, mar. 2020. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-196282

RESUMO

INTRODUCCIÓN: Las infecciones son una causa importante de morbimortalidad en los pacientes con cáncer (mortalidad estimada en 3%). La neutropenia febril conlleva con frecuencia el ingreso hospitalario de los pacientes oncológicos, incrementando el riesgo de infección nosocomial así como los costes sanitarios por ingresos. MÉTODOS: Estudio observacional ambispectivo (01/07/2015 - 31/12/2018) de los episodios de neutropenia febril posquimioterapia en población pediátrica. Se recogieron edad, sexo, percentil de peso (OMS), estancia hospitalaria (días), temperature (oC), aislamiento de germen, foco infeccioso, profilaxis o no antibiótica y antifúngica, cifras de hemoglobina (g/dl), plaquetas (/mm3), neutrófilos (/mm3), linfocitos (/mm3), monocitos (/mm3), proteína C reactiva (PCR) (mg/L) y procalcitonina (PCT) (ng/ml) al ingreso y días con neutropenia < 500/mm3. El análisis estadístico se realizó con el programa SPSSv.23. RESULTADOS: De 69 pacientes, se registraron 101 episodios. La estancia media fue de 7,43 días (mediana 6 días). Se aisló germen en un 44,6% de los episodios, no identificándose foco infeccioso en un 36% de los mismos. Se halló correlación inversa entre hemoglobina, plaquetas y linfocitos al ingreso con la estancia hospitalaria (-0,356 (p 0,001); -0,216 (p 0,042) y -0,216 (p 0,042) respectivamente). La estancia media fue mayor si al ingreso presentaron PCR > 90 mg/L (10,94 vs. 6,66 días p 0,017), si PCT > 1 ng/ml (16,50 vs. 6,77 días p 0,0002), si ≤ 100 neutrófilos (8,27 vs. 5,04 días p 0,039) y si hubo aislamiento microbiológico (9,54 vs. 5,78 días p 0,006). CONCLUSIÓN: La relación entre hemoglobina, plaquetas y linfocitos al ingreso con la estancia media es inversamente proporcional. Además, aquellos pacientes con ≤ 100 neutrófilos al ingreso, PCR > 90 mg/L y PCT > 1 ng/ml presentaron mayor estancia media. Estos factores podrían ser importantes en el manejo de la neutropenia febril en el paciente con cáncer infantil


INTRODUCTION: Infections are significant cause of morbidity and mortality in cancer patients (mortality is estimated at around 3%). Febrile neutropenia often leads to the hospitalisation of cancer patients, increasing the risk of nosocomial infection, as well as health costs due to the hospital admission. METHODS: An ambispective (01 July 2015 - 12 July 2018) observational study was conducted on all episodes of chemotherapy-induced febrile neutropenia in a paediatric population. A record was made of age, gender, weight percentile (WHO), length of hospital stay (days), temperature (oC), microbial isolation, infectious source, antibiotic or antifungal prophylaxis, haemoglobin (g/dl), platelets (/mm3), neutrophils (/mm3), lymphocytes (/mm3), monocytes (/mm3), CRP (mg/L) and procalcitonin (PCT) (ng/ml) on admission, and days with neutropenia < 500/mm3. Statistical analysis was performed using the SPSSv.23 program. RESULTS: The study included 69 patients, and 101 episodes were recorded. The mean stay was 7.43 days (median 6 days). Microbial isolation was found in 44.6% of the episodes, with no infectious source identified in 36% of them. An inverse correlation was found between haemoglobin, platelets, and lymphocytes on admission and the hospital stay (-0.356: P = .001, -0.216: P = .042, and -0.216: P = .042, respectively). The mean stay was greater if there was a CRP > 90 mg/L (10.94 vs. 6.66 days, P=.017), if PCT > 1 ng/ml (16.50 vs. 6.77 days, P = .0002), if ≤ 100 neutrophils (8.27 vs. 5.04 days P=.039) on admission, and if there was microbe isolation (9.54 vs. 5.78 days P = .006). CONCLUSION: The relationship between haemoglobin, platelets, and lymphocytes on admission and the mean stay is inversely proportional. In addition, those patients with ≤ 100 neutrophils, CRP > 90 mg/L, and PCT>1ng/ml on admission had a longer hospital stay


Assuntos
Humanos , Masculino , Feminino , Criança , Antineoplásicos/efeitos adversos , Neutropenia Febril/induzido quimicamente , Tempo de Internação , Antineoplásicos/uso terapêutico , Neutropenia Febril/epidemiologia , Neutropenia Febril/terapia , Infecções/epidemiologia , Infecções/microbiologia , Neoplasias/tratamento farmacológico , Estudos Prospectivos , Estudos Retrospectivos , Fatores de Risco
3.
An Pediatr (Engl Ed) ; 92(3): 141-146, 2020 Mar.
Artigo em Espanhol | MEDLINE | ID: mdl-31239190

RESUMO

INTRODUCTION: Infections are significant cause of morbidity and mortality in cancer patients (mortality is estimated at around 3%). Febrile neutropenia often leads to the hospitalisation of cancer patients, increasing the risk of nosocomial infection, as well as health costs due to the hospital admission. METHODS: An ambispective (01 July 2015 - 12 July 2018) observational study was conducted on all episodes of chemotherapy-induced febrile neutropenia in a paediatric population. A record was made of age, gender, weight percentile (WHO), length of hospital stay (days), temperature (oC), microbial isolation, infectious source, antibiotic or antifungal prophylaxis, haemoglobin (g/dl), platelets (/mm3), neutrophils (/mm3), lymphocytes (/mm3), monocytes (/mm3), CRP (mg/L) and procalcitonin (PCT) (ng/ml) on admission, and days with neutropenia<500/mm3. Statistical analysis was performed using the SPSSv.23 program. RESULTS: The study included 69 patients, and 101 episodes were recorded. The mean stay was 7.43 days (median 6 days). Microbial isolation was found in 44.6% of the episodes, with no infectious source identified in 36% of them. An inverse correlation was found between haemoglobin, platelets, and lymphocytes on admission and the hospital stay (-0.356: P=.001, -0.216: P=.042, and -0.216: P=.042, respectively). The mean stay was greater if there was a CRP>90mg/L (10.94 vs. 6.66 days, P=.017), if PCT>1ng/ml (16.50 vs. 6.77 days, P=.0002), if ≤ 100 neutrophils (8.27 vs. 5.04 days P=.039) on admission, and if there was microbe isolation (9.54 vs. 5.78 days P=.006). CONCLUSION: The relationship between haemoglobin, platelets, and lymphocytes on admission and the mean stay is inversely proportional. In addition, those patients with ≤100 neutrophils, CRP>90mg/L, and PCT>1ng/ml on admission had a longer hospital stay.


Assuntos
Antineoplásicos/efeitos adversos , Neutropenia Febril/induzido quimicamente , Tempo de Internação , Antineoplásicos/uso terapêutico , Criança , Neutropenia Febril/epidemiologia , Neutropenia Febril/terapia , Feminino , Humanos , Infecções/epidemiologia , Infecções/microbiologia , Masculino , Neoplasias/tratamento farmacológico , Estudos Prospectivos , Estudos Retrospectivos , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...